Review top news and interview highlights from the week ending August 12, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The 2 deaths, due to acute liver failure, occurred in patients treated in Kazakhstan and Russia.
A recent comparison of health-related quality of life scores also favored ide-cel over belantamab mafodotin treatment.
No such adverse events have occurred in the lower-dose group.
Nula-cel is intended to directly correct the mutation that causes sickle cell disease.
PBFT02, developed by Passage Bio, is delivered via intra cisterna magna administration to the brain.